USSTOCK.TODAY
Market Closed
Log in Sign up

NuCana plc ADR(NCNA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

NCNA
NCNA
NuCana plc ADR
At close Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$0.72
-0.11 ▼ -13.77%
Nov 19 at 7:34 PM ET (Korea 11/20 09:34)
$0.73
+0.02 ▲ +2.34%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -3.21Insider Own ⓘ 6.99%Shs Outstand ⓘ 4.8MPerf Week ⓘ -22.78%
Market Cap ⓘ 0.00BForward P/E ⓘ -EPS next Y ⓘ -Insider Trans ⓘ -Shs Float ⓘ 4.5MPerf Month ⓘ -25.36%
Enterprise Value ⓘ -0.02BPEG ⓘ -EPS next Q ⓘ -Inst Own ⓘ 1.52%Short Float ⓘ 3.11%Perf Quarter ⓘ -52.76%
Income ⓘ -0.01BP/S ⓘ -EPS this Y ⓘ -Inst Trans ⓘ -0.44%Short Ratio ⓘ 1.2Perf Half Y ⓘ -64.63%
Sales ⓘ 0.00BP/B ⓘ 19.84EPS next 5Y ⓘ -ROA ⓘ -39%Short Interest ⓘ 0.14MPerf YTD ⓘ -80.05%
Book/sh ⓘ 0.04P/C ⓘ 0.14EPS past 3/5Y ⓘ 83.42% 68.08%ROE ⓘ -48.64%52W High ⓘ -84.22% ($4.55)Perf Year ⓘ -78.56%
Cash/sh ⓘ 5.06P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -55.22%52W Low ⓘ -6.33% ($0.77)Perf 3Y ⓘ -99.97%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 99.5%Gross Margin ⓘ -Volatility(W/M) ⓘ 16.15% 9.05%Perf 5Y ⓘ -99.99%
Dividend TTM ⓘ -EV/Sales ⓘ -Sales Y/Y TTM ⓘ -Oper. Margin ⓘ -ATR (14) ⓘ 0.09Perf 10Y ⓘ -
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 5.15EPS Q/Q ⓘ -247.52%Profit Margin ⓘ -RSI (14) ⓘ 24.6Recom ⓘ 3
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 5.15Sales Q/Q ⓘ -SMA20 ⓘ -24.9% ($0.96)Beta ⓘ 2.44Target Price ⓘ $4750.48
Payout ⓘ -Debt/Eq ⓘ 0.03Earnings ⓘ 2026/8/13SMA50 ⓘ -33.9% ($1.09)Rel Volume ⓘ 0.96Prev Close ⓘ $0.83
Employees ⓘ 12LT Debt/Eq ⓘ 0.03EPS/Sales Surpr. ⓘ -SMA200 ⓘ -55.39% ($1.61)Avg Volume(3M) ⓘ 0.12MPrice ⓘ $0.72
IPO ⓘ 2017/9/28Option/Short ⓘ No/YesTrades ⓘ 335Volume ⓘ 111,285Change ⓘ -13.77%
Company
NCNA NCNANuCana plc ADR | NASD | Biotechnology Deep dive

💊 Nucana (formerly known as NuCana) is a UK-based, Edinburgh-headquartered clinical-stage biopharmaceutical company developing next-generation anticancer drugs by applying its proprietary ProTide technology to widely used nucleoside analog (anticancer) agents, with the goal of improving their efficacy and safety. Its lead assets are NUC-7738, which works via a novel mechanism of action inhibiting RNA polyadenylation and is being evaluated (including in combination therapy) in a Phase 1/2 trial for PD-1-resistant melanoma, and NUC-3373, a next-generation modification of 5-fluorouracil (5-FU).

Quote

Over the past 1 year, on the lower side

84% below its 1-year high.

Now $0.72
52w low$0.7752w high$4.55
52W Range0%
Volume ⓘ 111,285

Traded about as much as usual. That is 96% of its average volume.

C
Overall · average, with some caution
We judged 4 of the 8 questions below. 1 rate excellent and 2 need caution.
No data for growth, valuation, outlook, dividends, or not applicable.
Peer comparison Biotechnology

It ranks #556 of 598 in the industry

Based on market cap of $3M.

FAQ

FAQ

What kind of company is NCNA?

NCNA belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of NCNA?

The market cap of NCNA is approximately $3M, ranking 5,654 within its sector.

What is the 52-week high and low for NCNA?

NCNA has recorded a 52-week high of $4.55 and a low of $0.77.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels